| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Ivacaftor |
| Brand | Kalydeco® |
| Indication | For the treatment of children with CF aged 2 years and older and weighing less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. |
| Assessment Process | |
| Rapid review commissioned | 19/11/2015 |
| Rapid review completed | 18/12/2015 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 18/03/2016 |
| NCPE assessment completed | 12/10/2016 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price |
The HSE has approved reimbursement following confidential price negotiations.
